Denis Chem Lab Ltd Stock Price Today (NSE: DENISCHEM)

Denis Chem Lab Ltd

70.900.91 (1.27%)
Market Closed

Fundamental Score

...

Denis Chem Lab Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Denis Chem Lab Ltd share price today is 70.90, down 1.27% on NSE/BSE as of 18 June 2026. Denis Chem Lab Ltd (DENISCHEM) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 120.83 (Cr). The 52-week high for DENISCHEM share price is 109.00 and the 52-week low is 56.10. At a P/E ratio of 16.88x, DENISCHEM is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 9.77% and a debt-to-equity ratio of 0.09.

Denis Chem Lab Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
82.80
Low
68.35
Volume
9.6K
Change
-4.60%

Denis Chem Lab Ltd share price chart: -4.60% return over the past month. 52-week high ₹109.00, 52-week low ₹56.10.

Denis Chem Lab Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
71.2072.5068.4070.905.73K (Cr)
73.4573.4571.1071.812.60K (Cr)
73.4574.0072.1173.005.65K (Cr)
74.0074.0071.0073.454.54K (Cr)
72.0174.0071.0673.835.39K (Cr)
71.5073.7069.1372.0514.55K (Cr)
70.5071.0069.0070.908.65K (Cr)
72.7072.9069.9970.318.21K (Cr)
72.0072.0069.0070.004.30K (Cr)
71.4472.0069.7072.008.70K (Cr)

Denis Chem Lab Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
73.4573.4568.4070.90-3.47%
79.8082.8068.3573.00-8.52%
59.9085.7058.5178.38+30.85%
75.0076.0156.1056.54-24.61%
79.0084.8173.3076.86-2.71%
79.7086.8572.3577.99-2.15%
85.0187.9576.0078.48-7.68%
91.1093.0082.7587.85-3.57%
96.4097.3586.0091.67-4.91%
94.80103.0092.0094.94+0.15%
98.00103.0088.0092.89-5.21%
102.25104.7597.3098.75-3.42%

AI Research Briefing

Powered by Gemini · 2026-04-10

Micro-cap pharma play with promoter shenanigans and liquidity trap written all over it.

Research Confidence
5.0/10Moderate
OPERATOR-DRIVENBreakdown. 1M: -5.02%, 3M: -10.23%, 6M: -16.52%.P/E of 16.88x vs Industry P/E of 31.77x, appears cheap but micro-cap status warrants caution.

WHAT'S HAPPENING NOW (last 2-4 weeks)

Denis Chem Lab's stock has been under pressure, hitting a 52-week low of on March 30, 2026. The Daga group increased their stake to 9.64% on March 27, 2026, acquiring 2,67,499 shares, representing a 1.93% stake, in an off-market transaction. Trading window closed on April 1, 2026, ahead of FY26 results.

CORE STORY (THE REAL GAME)

Micro-cap pharma play vulnerable to promoter action and liquidity risk. Not a growth story, but a potential value unlock if management executes.

Why Now
  • Daga group increased stake to 9.64%
  • Q3 FY26 net profit increased 88.6% YoY
  • Stock trading near 52-week low
Potential Catalysts
  • Positive FY26 results
  • New order wins
  • Strategic acquisition
Key Risks
  • Micro-cap liquidity risk
  • Promoter action uncertainty
  • Negative news sentiment
Institutional Activity

Daga group increasing stake, but unclear if value accretive.

Macro Context

Indian pharma sector projected to reach $130 billion by 2030, but faces pricing pressures.

Cash Flow Quality

Free Cash Flow 5Y: ₹44.9 Cr, profit converting to cash.

3–6 Month Outlook

Near-term depends on FY26 results. Long-term hinges on management execution and sector growth.

Primary Thesis Risk

Promoter value extraction leading to shareholder wealth destruction.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Poor

Return on Equity (ROE)

9.77%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

13.89%

Returns generated on total capital deployed

Average

Oper. Profit Margin (5Y Avg)

10.82%

Average operating profit margin over 5 years

Good

Dividend Yield

1.72%

Annual dividend as % of current share price

Denis Chem Lab Ltd Valuation Check

Excellent

Price to Earnings (P/E)

16.88x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

31.77x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

38.98%

% shares held by company founders/management

Poor

FII Holding

0.01%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-37.39%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

-3.45%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

5.03%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

13.93%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

13.93%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.09x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

3.39x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

44.90 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Denis Chem Lab Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of DENISCHEM across key market metrics for learning purposes.

Positive Indicators

4 factors identified

Attractive Valuation (P/E: 16.88 vs Industry: 31.77)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Conservative Debt Levels (D/E: 0.09)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Cash Generation (₹44.90 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

3 factors identified

Below-Average Return on Equity (9.77%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Profit Decline Concern (-37.39%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Limited Institutional Interest (FII+DII: 0.01%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

Denis Chem Lab Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Denis Chem Lab Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
32/100
71
₹120.83
16.9
Average
9.77%
Poor
13.89%
Average
0.1
Excellent
13.93%
Good
5.03%
Good
1.72%
65.2/100
1844
₹433738.68
37.6
Average
16.86%
Good
20.21%
Excellent
0.1
Excellent
23.78%
Excellent
9.87%
Good
0.89%
67.9/100
6798
₹170445.88
68.6
Average
15.35%
Good
20.44%
Excellent
0.0
Excellent
10.41%
Good
11.65%
Good
0.47%
65.3/100
4538
₹126430.62
58.4
Average
26.52%
Excellent
27.05%
Excellent
0.3
Excellent
13.84%
Good
7.72%
Good
0.86%
Cipla Ltd...
CIPLA500087
59/100
1418
₹123059.76
22.6
Average
17.77%
Good
22.72%
Excellent
0.0
Excellent
28.68%
Excellent
9.97%
Good
0.85%
59.2/100
1319
₹105224.96
18.2
Average
17.96%
Good
22.69%
Excellent
0.2
Excellent
22.28%
Excellent
13.26%
Good
0.63%
Lupin Ltd...
LUPIN500257
66.7/100
2276
₹95148.15
22.0
Average
20.62%
Excellent
21.30%
Excellent
0.3
Excellent
54.88%
Excellent
8.11%
Good
0.58%
68.7/100
957
₹94253.78
18.7
Average
21.21%
Excellent
24.31%
Excellent
0.4
Excellent
25.92%
Excellent
10.27%
Good
1.17%
50.6/100
2420
₹92012.53
52.6
Average
14.68%
Average
15.98%
Good
0.6
Good
11.73%
Good
15.79%
Excellent
0.04%
28.8/100
1436
₹70798.69
20.7
Average
11.08%
Average
14.18%
Average
0.2
Excellent
3.87%
Average
6.55%
Good
0.33%
59.5/100
5452
₹67075.29
28.5
Average
19.39%
Good
20.38%
Excellent
0.2
Excellent
13.93%
Good
9.21%
Good
0.80%

Denis Chem Lab Ltd PE Ratio History

Historical price-to-earnings ratio for DENISCHEM — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 20248.04₹167.5020.8x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Denis Chem Lab Ltd Dividend History

Annual cash dividends paid by DENISCHEM — dividend yield 1.72%

Financial YearDividends Paid (₹ Cr)
FY 20253.47 Cr
FY 20242.78 Cr
FY 20232.08 Cr
FY 20221.04 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Denis Chem Lab Ltd Quarterly Performance

Latest quarterly metrics for DENISCHEM — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

-3.45%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-37.39%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

5.03%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

13.93%

Compounded annual net profit growth over 5 years

Denis Chem Lab Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for DENISCHEM — calculated from daily price history

40RSI 14
Neutral — RSI 40

Momentum is balanced — neither overbought nor oversold.

SMA 50
74
▼ Price below SMA 50 — Short-term bearish
SMA 200
83
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
8K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Denis Chem Lab Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Denis Chem Lab Ltd (DENISCHEM) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Denis Chem Lab Ltd

About DENISCHEM (Denis Chem Lab Ltd)

Denis Chem Lab Ltd is a pioneering force within the Indian pharmaceutical landscape, dedicated to the meticulous creation and distribution of sterile intravenous injectable solutio...ns for both human and animal healthcare needs. The company operates with a singular focus: to produce high-quality, life-saving medications delivered directly into the bloodstream. Their commitment extends beyond simply manufacturing; it embodies a dedication to precision, sterility, and efficacy, ensuring that each product meets the rigorous demands of modern medicine. From bustling urban hospitals to rural veterinary clinics, Denis Chem Lab aims to be a trusted provider of critical injectable therapies. The company’s diverse portfolio includes a spectrum of essential injectable medications, ranging from potent antibiotic treatments designed to combat severe infections, to carefully formulated diuretic solutions for fluid management. They also produce parenteral amino acid formulations to nourish patients unable to receive nutrition through conventional means, alongside plasma volume expanders crucial in emergency situations. Further strengthening their product line are specialized anti-anaerobic injections, fever-reducing anti-pyretic solutions, and sterile irrigation and dialysis fluids, all contributing to a comprehensive offering for a wide array of medical conditions. Each product is developed with scientific rigor and manufactured in state-of-the-art facilities. Beyond their own brand, Denis Chem Lab also extends their expertise to other pharmaceutical companies through contract manufacturing services. This collaborative approach leverages their advanced manufacturing capabilities and stringent quality control processes to support the broader healthcare industry. By partnering with third parties, Denis Chem Lab contributes to increasing the availability of vital medications, fostering innovation, and upholding the highest standards of pharmaceutical production. This dual focus – developing their own product line and providing contract manufacturing services – positions Denis Chem Lab as a versatile and reliable player in the pharmaceutical sector.

Company Details

Symbol:DENISCHEM
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Dr. Himanshu Chaitanya Patel B.E., B.S., Ph.D.
MD & Executive Director
Mr. Nirmal Himanshu Patel
Chief Executive Officer
Mr. Vikram Ramesh Joshi
Chief Finance Officer

DENISCHEM Share Price: Frequently Asked Questions

What is the current share price of Denis Chem Lab Ltd?

Denis Chem Lab Ltd (DENISCHEM) trades at ₹70.90 on NSE and BSE. Market cap ₹120.83 (Cr). Educational data only.

What is the P/E ratio of Denis Chem Lab Ltd?

Denis Chem Lab Ltd has a P/E of 16.88x vs industry average 31.77x.

What is the Bull Run score for Denis Chem Lab Ltd?

Denis Chem Lab Ltd has a Bull Run score of 32/100 based on 25+ financial parameters.

Does Denis Chem Lab Ltd pay dividends?

Denis Chem Lab Ltd has a dividend yield of 1.72%. Past dividends don't guarantee future payments.

What is the ROE of Denis Chem Lab Ltd?

Denis Chem Lab Ltd has ROE of 9.77%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Denis Chem Lab Ltd?

Denis Chem Lab Ltd has debt-to-equity of 0.09.

Is Denis Chem Lab Ltd a good investment?

Bull Run gives Denis Chem Lab Ltd a score of 32/100. This is not investment advice — consult a SEBI-registered advisor.